August 23, 2011
Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
- /
- /
- /
– Host-Targeted Antiviral Blocks JC Virus Entry – PR Newswire ATLANTA, Aug. 16, 2011 /PRNewswire/ — Inhibikase Therapeutics, Inc., an emerging leader in…
